Oxford Nanopore Technologies Announces Participation in €12M READNA Project
News Dec 04, 2008
Oxford Nanopore Technologies has announced its participation in the Revolutionary Approaches and Devices for Nucleic Acid analysis project (READNA).
The newly-launched READNA consortium includes researchers from 16 academic and industrial institutions and will receive €12m in funding over four years, under the European Union’s Seventh Framework Programme (FP7).
As part of the consortium, Oxford Nanopore will receive €730,000 in grant funding to support the development of its nanopore technology into an early exonuclease/nanopore DNA sequencing system.
The Company will also work on projects to integrate protein nanopores and solid-state materials for the further progression of nanopore sequencing, the development of a new technique that uses nanopores for genome-wide methylation studies and the development of droplet-based bilayer arrays for multiplexed genotyping.
Oxford Nanopore will collaborate closely with researchers from the University of Oxford, including Professor Hagan Bayley’s Chemical Biology group, the Biological Physics group and the Wellcome Trust Centre for Human Genetics. The University will receive €2m to support READNA projects.
Specific goals of the project include:
• Development of a new generation of rapid and cost effective sequencing methodologies
• Single molecule detection of DNA molecules in nanosystems using nanopores and nanochannels
• Improvement of elements of existing sequencing systems
• Methods for the detection and the enrichment of rare mutations from peripheral patient samples
• Combining RNA and DNA analysis in a single analytical device
• Development of methods for genome-wide analysis of DNA methylation at a high resolution
• Development of cost-effective high resolution HLA typing
• Development of assays for effective high-resolution genotyping of copy number variations
• Overall, the project aims to progress towards a target of sequencing a complete human genome for €1000; the promotion of new sequencing technologies is central to this goal.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.